PRAX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

PRAX ▼ -3.43% at T+20d

LONG call ✗ call lost -3.43% · α vs SPY -9.73% · entry $343.60 → $331.81

Next anchor: T+60d in 29d

Currently $250.33 · -27.14% from $343.60 entry

Entry anchored
Apr 13, 03:59 PM ET
via Databento tick

T+1d

-1.07%

call -1.07% · α -1.84%

$339.93

settled 8w ago

T+5d

-0.80%

call -0.80% · α -2.20%

$340.84

settled 7w ago

T+20d

-3.43%

call -3.43% · α -9.73%

$331.81

settled 29d ago

T+60d

—

call — · α —

—

in 29d

Price Chart

Loading chart...

Executive Summary

Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl to treat essential tremor, with a PDUFA target action date of January 29, 2027. The FDA does not plan to hold an advisory committee meeting, accelerating the review timeline.

Actionable Insight

The lack of an advisory committee meeting reduces regulatory risk and increases approval probability ahead of the PDUFA date. Traders should monitor for any FDA updates and position ahead of the January 2027 decision, especially given the drug's Breakthrough Therapy status and strong Phase 3 data.

Key Facts

FDA accepted NDA for ulixacaltamide HCl for essential tremor with PDUFA date of January 29, 2027
No advisory committee meeting planned, indicating streamlined review process
NDA supported by positive Phase 3 Essential3 trial results showing statistically and clinically significant efficacy
Ulixacaltamide received Breakthrough Therapy Designation in December 2025
Drug was generally well tolerated with no drug-related serious adverse events

Financial Impact

Potential first-in-class therapy for essential tremor, a market with high unmet need; commercial launch preparation underway

revenuemarketCapvaluation

Risk Factors

Regulatory delay or rejection despite PDUFA date
Commercial execution risk post-approval
Competition from emerging therapies in CNS space

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3273225

8 reports for PRAX

T+1T+5T+20T+60

80% Hit rate 4 of 5 directional calls best @ T+20▲ +8.87%Apr 6, 2026

Filters

Reports for PRAX — sortable, filterable
	Type				Now
Jun 2, 2026 7d ago	Press Release NEUTRAL ★ 1/10	$278.93 $264.75	▼ −5.08%	▼ −5.49%	$250.33 (−10.25%)
May 7, 2026 4w ago	Press Release BULLISH ★ 8/10	$333.28 $330.02	▼ −0.98%	▼ −1.81%	$250.33 (−24.89%)
May 4, 2026 5w ago	Press Release NEUTRAL ★ 2/10	$333.30 $338.07	▲ +1.43%	▲ +0.05%	$250.33 (−24.89%)
Apr 14, 2026 8w ago	Press Release BULLISH ★ 8/10	$343.60 $339.93	▼ −1.07%	▼ −1.84%	$250.33 (−27.14%)
Apr 6, 2026 9w ago	Press Release BULLISH ★ 8/10	$310.11 $306.69	▼ −1.10%	▼ −1.17%	$250.33 (−19.28%)
Mar 30, 2026 10w ago	Press Release BULLISH ★ 8/10	$322.19 $319.28	▼ −0.90%	▼ −1.65%	$250.33 (−22.30%)
Feb 28, 2026 14w ago	Institutional Cluster BULLISH ★ 8/10	$330.59 $318.22	▼ −3.74%	▼ −2.83%	$250.33 (−24.28%)
Feb 28, 2026 14w ago	Institutional Cluster BULLISH ★ 6/10	$330.59 $318.22	▼ −3.74%	▼ −2.83%	$250.33 (−24.28%)

US Market Status

Market Closed — Opens Thu (10h 58m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access